MOBOCERTINIB DISCONTINUED (has an active metabolite) | MOBOCERTINIB | ATC L01EB10
ANTINEOPLASTIC KINASE INHIBITOR TREATMENT OF NSCLC WITH EGFR EXON 20 INSERTION MUTATIONS INHIBITS KINASES HER2, HER4 AND BLK WITH IC50 BELOW 2 NANOMOLAR | ORAL | Tmax 4 HOUR F 37 PERCENT VD 3509 LITER PPB 99.3 PERCENT Cl 138 LITER / HOUR HT 18 HOUR SOLUBILITY 17 MILLIGRAM PER MILLILITER AT PH 6.8 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) (MUTATED) HER2 HER4 BLK | Epidermal growth factor receptor UNIPROT P00533 EGFR -- Receptor tyrosine-protein kinase erbB-2 UNIPROT P04626 ERBB2 more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |